FDA Logo links to FDA home page
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

FDA Home Page | Dockets Home Page | Dockets Contacts and Location | Operating Status

horizonal rule

Dockets Management
Dockets Entered On July 1, 2005
Table of Contents
Docket # Title
1979P-0418 Argon laser
1981P-0001 Laser Lumia Projection System
1999V-0555 Laser images dual RGB projector
2003V-0124 Laser Light Show
2004P-0060 Health Claim Petition: Glucosamine Sulfate and Osteoarthritis
2004P-0223 Whole Grain Descriptive Claims
2004P-0550 Determine that AstraZeneca LP's Xylocaine (lidocaine) 10% Oral Spray (NDA 14-394) was voluntarily withdrawn or withheld from sale for reasons other than safety or effficacy
2004P-0557 ANDA for a generic version of Efudex Cream(fluorouracil) cream
2005D-0021 International Conference on Harmonisation; Draft Guidance on Q8 Pharmaceutical Development
2005D-0047 Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications
2005D-0062 Draft Guidance FDAs Drug Watch for Emerging Drug Safety
2005D-0103 Guidance for Industry on Using a Centralized IRB Process in Multicenter Clinical Trials
2005D-0112 Guidance for Industry on Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
1979P-0418 Argon laser
VRA 7 HFZ-200 to Brevarde Community College Vol #: 1
1981P-0001 Laser Lumia Projection System
VRA 12 HFZ-200 to Lighting Systems Design, Inc Vol #: 1
1999V-0555 Laser images dual RGB projector
VRA 3
Attachment A, B
HFZ-200 to Cook Arts, Science, and Technology Center Vol #: 1
2003V-0124 Laser Light Show
VRA 2
Attachment A, B
HFZ-200 to Universal Studios Florida Vol #: 1
2004P-0060 Health Claim Petition: Glucosamine Sulfate and Osteoarthritis
LET 13 HFS-800 to Hogan & Hartson LLP Vol #: 3
2004P-0223 Whole Grain Descriptive Claims
C 19 ConAgra Foods Inc Vol #: 5
2004P-0550 Determine that AstraZeneca LP's Xylocaine (lidocaine) 10% Oral Spray (NDA 14-394) was voluntarily withdrawn or withheld from sale for reasons other than safety or effficacy
LET 1 HFD-5 to Arent Fox PLLC Vol #: 1
2004P-0557 ANDA for a generic version of Efudex Cream(fluorouracil) cream
LET 1 HFD-5 to Valeant Pharmaceuticals International Vol #: 1
2005D-0021 International Conference on Harmonisation; Draft Guidance on Q8 Pharmaceutical Development
C 6 Boehringer Ingelheim Pharmaceuticals Inc Vol #: 1
EMC 1 PDA Vol #: 1
EMC 2 Amgen Inc Vol #: 1
2005D-0047 Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications
C 5 Vaccines Research Advocate Vol #: 1
2005D-0062 Draft Guidance FDAs Drug Watch for Emerging Drug Safety
C 1 National Organization for Rare Disorders Inc Vol #: 1
C 2 Ovation Pharmaceuticals Inc Vol #: 1
2005D-0103 Guidance for Industry on Using a Centralized IRB Process in Multicenter Clinical Trials
EMC 1 R Reinhard, G Broder, T Gibson, D Crawford Vol #: 1
2005D-0112 Guidance for Industry on Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
EMC 2 American Society of Clinical Oncology Vol #: 1
EMC 3 Merck & Co. Inc Vol #: 1
EMC 4 Abbott Global Medical and Scientific Affairs Vol #: 1

Page created on July 18, 2005 dp

horizonal rule

Dockets Home| Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | A-Z Index | Contact FDA | Privacy | Accessibility

FDA/Dockets Management